USNANYSEMedicinal Chemicals & Botanical ProductsFiscal year ends January 3
USANA HEALTH SCIENCES INC
Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 13, 2026
$14.89−0.65 (-4.18%)
Close on Oct 19, 2026
- Market cap
- $275.26M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
78.3%−3.3 pts over 5 years
Operating margin
4.0%−11.5 pts over 5 years
Net margin
1.2%−9.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +8.3% | -2.5% | -4.0% | +0.1% | |
| Gross profit | +4.5% | -3.4% | -4.8% | -0.5% | |
| Operating income | -43.6% | -29.7% | -26.7% | -12.5% | |
| Net income | -74.4% | -46.3% | -38.7% | -19.5% | |
| EPS, diluted | -73.5% | -45.5% | -37.0% | -16.7% | |
| Free cash flow | -83.3% | -55.0% | -43.3% | -20.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 33.0% | 31.4% | 2.0% | |
| Return on assets | 22.4% | 21.5% | 1.4% | |
| Current ratio | 2.01 | 2.53 | 2.24 | |
| Interest coverage | 312.2× | 348.1× | 44.5× | |
| Inventory turnover | 2.8× | 2.5× | 2.3× | |
| Capex to revenue | 3.3% | 1.3% | 1.5% | |
| Diluted shares | 25M | 21M | 19M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Usana Health Sciences generated $379.11M from operations and spent $313.32M on capital expenditure, dividends and share buybacks. 20% of that went back into the business.
Generated
$379.11M
Used
$313.32M
Capital expenditure$61.55M20%Dividends$00%Share buybacks$251.77M80%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin1.2%
×Asset turnover1.24×
×Equity multiplier1.40×
=Return on equity, FY20252.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 1.2% | 1.24× | 1.40× | 2.0% |
| FY2024 | 4.9% | 1.24× | 1.34× | 8.2% |
| FY2023 | 6.9% | 1.50× | 1.32× | 13.7% |
| FY2022 | 6.9% | 1.70× | 1.42× | 16.7% |
| FY2021 | 9.8% | 1.95× | 1.46× | 27.8% |
| FY2020 | 11.0% | 1.96× | 1.46× | 31.4% |
| FY2019 | 9.5% | 1.98× | 1.44× | 27.1% |
| FY2018 | 10.6% | 2.22× | 1.42× | 33.5% |
| FY2017 | 6.0% | 2.12× | 1.44× | 18.2% |
| FY2016 | 9.9% | 2.25× | 1.47× | 33.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$10.76M
- Cash generatingOperating cash flow above zero$22.35M
- Return on assets improvedROA up on the prior year6.6% → 1.4%
- Earnings backed by cashOperating cash flow above net income$22.35M vs $10.76M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.00 → 2.24
- No dilutionShare count did not rise19M → 19M
- Gross margin improvedGross margin up on the prior year81.13% → 78.29%
- More efficientAsset turnover rose1.35 → 1.24